Spero Therapeutics, Inc. Accounts Payable
Spero Therapeutics, Inc. (SPRO) had Accounts Payable of $155.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-12
- 2026-06-30: Accounts Payable, Current $155.00K.
- 2026-03-31: Accounts Payable, Current $217.00K.
- 2025-12-31: Accounts Payable, Current $693.00K.
- 2025-09-30: Accounts Payable, Current $1.40M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $155.00K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $217.00K 10-Q · filed 2026-05-13 |
| 2025-12-31 | $693.00K 10-Q · filed 2026-08-12 |
| 2025-09-30 | $1.40M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $780.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $1.76M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $7.31M 10-K · filed 2026-03-26 |
| 2024-09-30 | $6.09M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $2.70M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $3.07M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $1.38M 10-K · filed 2025-03-27 |
| 2023-09-30 | $1.10M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $1.31M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $583.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $617.00K 10-K · filed 2024-03-13 |
| 2022-09-30 | $2.58M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $1.71M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $4.78M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $1.10M 10-K · filed 2023-03-30 |
| 2021-09-30 | $3.16M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $1.63M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $3.83M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $1.16M 10-K · filed 2022-03-31 |
| 2020-09-30 | $2.48M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $1.56M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $8.95M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $4.15M 10-K · filed 2021-03-11 |
| 2019-09-30 | $2.52M 10-Q · filed 2019-11-04 |
| 2019-06-30 | $1.04M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $557.00K 10-Q · filed 2019-05-09 |
| 2018-12-31 | $3.60M 10-K · filed 2020-03-16 |
| 2018-09-30 | $1.36M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $705.00K 10-Q · filed 2018-08-09 |
| 2018-03-31 | $982.00K 10-Q · filed 2018-05-10 |
| 2017-12-31 | $3.47M 10-K · filed 2019-03-14 |
| 2017-09-30 | $2.01M 10-Q · filed 2017-12-14 |
| 2016-12-31 | $1.14M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |